-
1.发明授权Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices 失效来自造血祖细胞的三维装置中的淋巴组织特异性细胞产生公开(公告)号：US07192769B2
公开(公告)日：2007-03-20
申请号：US10161097
申请日：2002-05-31
IPC分类号： C12N5/06
CPC分类号： C12Q1/24 , A61K2035/122 , A61K2035/124 , A61K2039/5158 , C12N5/0636 , C12N5/0647 , C12N2501/23 , C12N2501/59 , C12N2502/11 , G01N33/5008 , G01N33/5011 , G01N33/505 , G01N33/5073 , G01N33/5094 , G01N2500/00
摘要： The invention relates to a method for lymphoid tissue-specific cell production from hematopoietic progenitor cells in unique, three-dimensional culture devices, in the presence of antigen presenting cells and lymphoreticular stromal cells, and in the absence of exogenously added growth factors. The resulting lymphoid tissue-specific cells may be isolated at any sequential stage of differentiation and further expanded. The lymphoid tissue-specific cells also may be genetically altered at any stage of the process.
摘要翻译： 本发明涉及在存在抗原呈递细胞和淋巴网状基质细胞的情况下以及在不存在外源性生长因子的情况下，在独特的三维培养装置中由造血祖细胞产生淋巴组织特异性细胞的方法。 所得到的淋巴组织特异性细胞可以在任何分化阶段分离并进一步扩增。 淋巴组织特异性细胞也可以在该过程的任何阶段进行遗传改变。
-
2.发明授权Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices 失效来自造血祖细胞的三维装置中的淋巴组织特异性细胞产生公开(公告)号：US06548299B1
公开(公告)日：2003-04-15
申请号：US09574749
申请日：2000-05-18
IPC分类号： C12N506
CPC分类号： C12Q1/24 , A61K2035/122 , A61K2035/124 , A61K2039/5158 , C12N5/0636 , C12N5/0647 , C12N2501/23 , C12N2501/59 , C12N2502/11 , G01N33/5008 , G01N33/5011 , G01N33/505 , G01N33/5073 , G01N33/5094 , G01N2500/00
摘要： The invention relates to a method for lymphoid tissue-specific cell production from hematopoietic progenitor cells in unique, three-dimensional culture devices, in the presence of lymphoreticular stromal cells and in the absence of exogenously added growth factors. The resulting differentiated progeny. The lymphoid tissue-specific cells may be isolated at any sequential stage of differentiation and further expanded. The lymphoid tissue-specific cells also may be genetically altered at any stage of the process.
摘要翻译： 本发明涉及在独特的三维培养装置中，在淋巴网状基质细胞存在下和在不存在外源性生长因子的情况下由造血祖细胞产生淋巴组织特异性细胞的方法。 所产生的差异后代。 可以在分化的任何顺序阶段分离淋巴组织特异性细胞并进一步扩增。 淋巴组织特异性细胞也可以在该过程的任何阶段进行遗传改变。
-
3.发明申请CAR RECEPTOR AS A MEDIATOR OF MIGRATORY CELL CHEMOTAXIS AND/OR CHEMOKINESIS 审中-公开CAR受体作为转染细胞化学和/或化学反应的介质公开(公告)号：US20120329153A1
公开(公告)日：2012-12-27
申请号：US13118511
申请日：2011-05-30
IPC分类号： C12N5/0789 , C12N5/077
CPC分类号： A61L27/3821 , A61K31/00 , A61K31/137 , A61K31/138 , A61K31/59 , A61K38/195 , A61K38/2006 , A61K45/06 , A61L27/3804 , A61L27/3847 , A61K2300/00
摘要： This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating io hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.
摘要翻译： 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮，内皮或间质来源的CaR受体表达细胞的运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源或排斥的运动。 本发明还涉及用于操作io血型祖细胞和相关产品的方法。 特别地，本发明包括使用CaR受体相关组合物来增强造血祖细胞的动员，提高靶向细胞到骨髓的效率和/或调节造血祖细胞功能的方法和产品。
-
4.发明授权CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis 有权CaR受体作为迁移性细胞趋化性和/或趋化因子的介质公开(公告)号：US07951364B2
公开(公告)日：2011-05-31
申请号：US11429902
申请日：2006-05-08
IPC分类号： A01N63/00
CPC分类号： A61L27/3821 , A61K31/00 , A61K31/137 , A61K31/138 , A61K31/59 , A61K38/195 , A61K38/2006 , A61K45/06 , A61L27/3804 , A61L27/3847 , A61K2300/00
摘要： This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.
摘要翻译： 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮，内皮或间质来源的CaR受体表达细胞的运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源或排斥的运动。 本发明还涉及操纵造血祖细胞和相关产品的方法。 特别地，本发明包括使用CaR受体相关组合物来增强造血祖细胞的动员，提高靶向细胞到骨髓的效率和/或调节造血祖细胞功能的方法和产品。
-
5.发明授权CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis 失效CaR受体作为迁移性细胞趋化性和/或趋化因子的介质公开(公告)号：US07176243B2
公开(公告)日：2007-02-13
申请号：US10002854
申请日：2001-11-01
IPC分类号： A01N33/02
CPC分类号： A61L27/3821 , A61K31/00 , A61K31/137 , A61K31/138 , A61K31/59 , A61K38/195 , A61K38/2006 , A61K45/06 , A61L27/3804 , A61L27/3847 , A61K2300/00
摘要： This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.
摘要翻译： 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮，内皮或间质来源的CaR受体表达细胞的运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源或排斥的运动。 本发明还涉及操纵造血祖细胞和相关产品的方法。 特别地，本发明包括使用CaR受体相关组合物来增强造血祖细胞的动员，提高靶向细胞到骨髓的效率和/或调节造血祖细胞功能的方法和产品。
-
公开(公告)号：US07141363B2
公开(公告)日：2006-11-28
申请号：US10191988
申请日：2002-07-09
CPC分类号： G01N33/5029 , A61K38/00 , C07K14/521 , C07K14/8114 , G01N33/5008 , G01N33/5011 , G01N33/5044 , G01N33/5047 , G01N33/505 , G01N33/5058 , G01N33/5064 , G01N33/5088
摘要： This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of cells of hematopoietic, neural, epithelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. More specifically, specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. Other sites include tumor sites, sites of pathogenic infection, and germ cell bearing sites.
-
7.发明授权公开(公告)号：US06448054B1
公开(公告)日：2002-09-10
申请号：US09546153
申请日：2000-04-07
IPC分类号： C12N999
CPC分类号： G01N33/5029 , A61K38/00 , C07K14/521 , C07K14/8114 , G01N33/5008 , G01N33/5011 , G01N33/5044 , G01N33/5047 , G01N33/505 , G01N33/5058 , G01N33/5064 , G01N33/5088
摘要： This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of cells of hematopoietic, neural, epithelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. More specifically, specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. Other sites include tumor sites, sites of pathogenic infection, and germ cell bearing sites.
摘要翻译： 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮或间质来源的细胞运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 更具体地，特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源的运动或排斥。 其他部位包括肿瘤部位，病原体感染部位和生殖细胞承载部位。
-
8.发明授权公开(公告)号：US07775469B2
公开(公告)日：2010-08-17
申请号：US11407477
申请日：2006-04-20
CPC分类号： G01N33/5029 , A61K38/00 , C07K14/521 , C07K14/8114 , G01N33/5008 , G01N33/5011 , G01N33/5044 , G01N33/5047 , G01N33/505 , G01N33/5058 , G01N33/5064 , G01N33/5088
摘要： This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of cells of hematopoietic, neural, epithelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. More specifically, specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. Other sites include tumor sites, sites of pathogenic infection, and germ cell bearing sites.
摘要翻译： 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮或间质来源的细胞运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 更具体地，特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源的运动或排斥。 其他部位包括肿瘤部位，病原体感染部位和生殖细胞承载部位。
-
9.发明授权
公开(公告)号：US5677139A
公开(公告)日：1997-10-14
申请号：US426782
申请日：1995-04-21
IPC分类号： C12N5/02 , C12N5/0783 , G01N33/50 , C12Q1/02
CPC分类号： C12N5/0636 , G01N33/5005 , C12N2501/23 , C12N2502/11 , C12N2503/00
摘要： The invention involves a method for the in vitro T cell production. A monolayer of non-human primate thymic stromal cells are cocultured in vitro with primate hematopoietic T cell progenitor cells. This results in the differentiation and growth of mature T cells. The T cells may be isolated at any sequential stage of differentiation and further expanded by coculture with a mitogenic agent. The T cells also may be genetically altered at any stage of the process. The effect of agents on the growth and differentiation of T cells may be measured by comparing a coculture containing the agent with a control coculture and comparing the differentiation or growth of the T cells progenitor cells in the test culture with the control culture. Kits and novel populations of T cells are provided.
摘要翻译： 本发明涉及体外T细胞生产的方法。 单层非人灵长类动物胸腺基质细胞在体外与灵长类动物造血T细胞祖细胞共培养。 这导致成熟T细胞的分化和生长。 可以在分化的任何连续阶段分离T细胞，并通过与促有丝分裂剂共同培养进一步扩增。 T细胞也可以在该过程的任何阶段进行遗传改变。 试剂对T细胞生长和分化的影响可以通过将含有该试剂的共培养物与对照共培养进行比较来测量，并将测试培养物中T细胞祖细胞的分化或生长与对照培养物进行比较。 提供试剂盒和新型T细胞群体。
-
公开(公告)号：US08088622B2
公开(公告)日：2012-01-03
申请号：US12331117
申请日：2008-12-09
申请人： David T. Scadden , Tao Cheng
发明人： David T. Scadden , Tao Cheng
IPC分类号： C12N15/87
CPC分类号： C12N5/0647 , A01K2217/05 , A61K48/00 , A61K2035/124 , C07K2319/00 , C12N2501/125 , C12N2501/145 , C12N2501/23 , C12N2501/26 , C12N2501/405
摘要： The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21cip1/waf1 and/or p27, cyclin dependent kinase inhibitors. In the absence of p27 activity, progenitor cells move into the cell cycle and proliferate; whereas in the absence of p21 activity, stem cells move into the cell cycle and proliferate without losing their pluripotentiality (i.e., their ability to differentiate into the various cell lines found in the blood stream). Any type of stem cell or progenitor cell, or precursor thereof, including, but not limited to, hematopoietic, gastrointestinal, lung, neural, skin, muscle, cardiac muscle, renal, mesenchymal, embryonic, fetal, or liver cell may be used in accordance with the invention. The present invention provides a method of expanding a cell population, cells with decreased p27 and/or p21 activity, transgenic animals with a disrupted p27 and/or p21 gene, pharmaceutical compositions comprising the cells of the invention, and methods of using these cells in gene therapy (e.g., stem cell gene therapy) and bone marrow transplantation.
摘要翻译： 干细胞或祖细胞群或其前体的扩增可以通过破坏或抑制p21cip1 / waf1和/或p27细胞周期蛋白依赖性激酶抑制剂来实现。 在没有p27活性的情况下，祖细胞进入细胞周期并增殖; 而在没有p21活性的情况下，干细胞进入细胞周期并增殖而不丧失其多能性（即，它们分化成血液中发现的各种细胞系的能力）。 包括但不限于造血，胃肠，肺，神经，皮肤，肌肉，心肌，肾，间充质，胚胎，胎儿或肝细胞的任何类型的干细胞或祖细胞或其前体可用于 根据本发明。 本发明提供了扩增细胞群的方法，具有降低的p27和/或p21活性的细胞，具有破坏的p27和/或p21基因的转基因动物，包含本发明细胞的药物组合物，以及使用这些细胞的方法 基因治疗（如干细胞基因治疗）和骨髓移植。
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.032 秒)
